Figure 3
From: Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
Schematic representation of clonal evolution in patients treated with anti-EGFR monoclonal antibodies. The lines are examples of the likely levels of mutated cfDNA detected at different stages of treatment. APC mutation (black line) reflects tumor burden, which decreases after treatment but increases again when resistance develops. Different KRAS and NRAS mutations (green, purple and blue lines) are detected in cfDNA at the acquisition of resistance, before relapse is clinically manifest.